BACKGROUND: Exosomes, cell-derived vesicles encompassing lipids, DNA, proteins 
coding genes and noncoding RNAs (ncRNAs) are present in diverse body fluids. 
They offer novel biomarker and drug therapy potential for diverse diseases, 
including cancer.
MATERIALS AND METHODS: Using gene ontology, exosomal genes database and 
GeneCards metadata analysis tools, a database of cancer-associated protein 
coding genes and ncRNAs (n=2,777) was established. Variant analysis, expression 
profiling and pathway mapping were used to identify putative pancreatic cancer 
exosomal gene candidates.
RESULTS: Five hundred and seventy-five protein-coding genes, 26 RNA genes and 
one pseudogene directly associated with pancreatic cancer were identified in the 
study. Nine open reading frames (ORFs) encompassing enzymes, apoptosis and 
transcriptional regulators, and secreted factors and five cDNAs (enzymes) 
emerged from the analysis. Among the ncRNA class, 26 microRNAs (miRs), one 
pseudogene, one long noncoding RNA (LNC) and one antisense gene were identified. 
Furthermore, 22 exosome-associated protein-coding targets (a cytokine, enzymes, 
membrane glycoproteins, receptors, and a transporter) emerged as putative leads 
for pancreatic cancer therapy. Seven of these protein-coding targets are 
FDA-approved and the drugs-based on these could provide repurposing 
opportunities for pancreatic cancer.
CONCLUSION: The database of exosomal genes established in this study provides a 
framework for developing novel biomarkers and drug therapy targets for 
pancreatic cancer.